Restaurant Brands Asia Regulatory Approval

Restaurant Brands Asia Acquisition Worth ₹1.1 Cr

Restaurant Brands Asia was allotted 11,00,000 shares of Navitas Anant Renewables Two for ₹1.10 Crore, a 26% stake. The SPV will supply solar power to its restaurants.

Value

₹1.10 Cr

Restaurant Brands Asia Product Launch

Burger King India launches a limited-edition Avengers: Doomsday Collection across nationwide restaurants. The menu features themed burgers, sides, and merchandise starting at ₹199.

Restaurant Brands Asia Earnings Call Transcript: Key Takeaways

Consolidated revenue grew 20% YoY on 14% SSSG, with company EBITDA rising sharply on restaurant margin gains. Indonesia is near restaurant-level break-even, but management gave no quantified forward guidance.

Restaurant Brands Asia Capital Structure Change

Restaurant Brands Asia will subscribe up to ₹131.23 Crore in preference shares of its Indonesian subsidiary. The cash infusion funds PT Sari Burger's business needs.

Value

₹131.2 Cr

Execution

Tranches; indicative completion by 30-06-2027

Restaurant Brands Asia Management Change

Restaurant Brands Asia appointed nine persons on October 29, 2026, including two directors, a CEO and senior management heads. Shivkumar Dega joins as a non-executive independent director.

Restaurant Brands Asia Results Update

Restaurant Brands Asia released a press release on Q2 FY27 results showing consolidated revenue up 20.1% to Rs 8,448 million. Standalone profit after tax turned positive at Rs 155.85 million.

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.